Lanicor Ampullen

Digoxin, the active ingredient in Lanicor Ampullen, is a cardiac glycoside presented as an injectable ampoule for intravenous use. It is employed in the management of heart failure and certain atrial arrhythmias, such as atrial fibrillation and atrial flutter, by improving cardiac contractility and modulating conduction.

GNH USA supplies Lanicor Ampullen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and healthcare institutions worldwide, with robust quality assurance and regulatory compliance to meet global market requirements, including cold‑chain logistics for injectable products.

Digoxin is used in cardiac conditions where modulation of contractility and conduction is required. - Heart failure: improves ventricular contractility and reduces symptoms of congestion. - Atrial fibrillation: provides rate control by slowing atrioventricular nodal conduction. - Atrial flutter: assists in ventricular rate control during flutter episodes.

Digoxin may cause a range of adverse reactions, varying from mild to potentially life‑threatening.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Visual disturbances: blurred vision or color halos. - Fatigue: feeling of tiredness or weakness. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Cardiac arrhythmias: potentially dangerous rhythm disturbances. - Severe bradycardia or heart block: marked slowing of heart rate. - Hyperkalemia: elevated blood potassium levels. - Allergic reactions: rash, itching, or anaphylaxis.

When using Digoxin, several precautions should be observed to minimize toxicity and ensure safe therapy. - Dose adjustment: tailor the dose to renal function and age to avoid accumulation. - Therapeutic monitoring: measure serum digoxin concentrations and electrolytes regularly. - Electrolyte balance: correct hypokalemia, hypomagnesemia, and hypercalcemia before treatment. - Cardiac monitoring: observe for new arrhythmias, especially in patients with pre‑existing conduction disorders. - Contraindications: avoid use in patients with ventricular fibrillation or severe digitalis toxicity. - Store at ambient temperature: keep ampoules in the original packaging, protect from light and moisture, and do not freeze.

Digoxin’s pharmacokinetics and electrophysiologic effects can be altered by several concomitant medicines.

Major Interactions (Avoid): - Amiodarone: markedly increases digoxin levels, raising toxicity risk. - Quinidine: potentiates digoxin’s effect on cardiac conduction, leading to arrhythmias. - Spironolactone: may elevate serum digoxin concentrations through reduced renal clearance.

Moderate Interactions (Monitor Closely): - Beta‑blockers: additive bradycardic effect, requiring heart‑rate monitoring. - Diuretics (e.g., furosemide): can cause electrolyte disturbances that predispose to digoxin toxicity. - Calcium channel blockers (e.g., verapamil): may increase digoxin levels modestly; monitor serum concentrations.